Transarterial chemoembolization for hepatocellular carcinoma: Significance of extrahepatic collateral supply

Indian Journal of Cancer

Volumn 48, Issue 3, 2011, Pages 339-344

  Paul, S B ^a   Gamanagatti, S R ^a   Mukund, A ^a   Abbas, S Z ^a   Acharya, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Extrahepatic supply; hepatocellular carcinoma; multiphasic computed tomography; percutaneous acetic acid ablation; transarterial chemoembolization

Indexed keywords

ACETIC ACID; CISPLATIN; DOXORUBICIN; GELFOAM; IODINATED POPPYSEED OIL;

ARTICLE; CANCER CONTROL; CANCER STAGING; CANNULATION; CHEMOEMBOLIZATION; EXTRAHEPATIC COLLATERAL ARTERIAL SUPPLY; FOLLOW UP; GASTRODUODENAL ARTERY; HUMAN; INTERNAL MAMMARY ARTERY; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN; SUPERIOR MESENTERIC ARTERY; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR ABLATION;

ALPHA-FETOPROTEINS; BLOOD CELL COUNT; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; HUMANS; LIVER; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 80053967186     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.84941     Document Type: Article

References (20)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
2. Pisani P, Parkin DM, Ferlay J. Estimates of the world wide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-3.
3. Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: Value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007;72 Suppl 1:117-23. (Pubitemid 350256675)
4. Sarin SK, Thakur V, Guptan RC, Saigal S, Malhotra V, Thyagarajan SP, et al. Profile of hepatocellular carcinoma in India. An insight into the possible etiologic associations. J Gastronterol Hepatol 2001;16:666-73. (Pubitemid 34188842)
5. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
6. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9. (Pubitemid 44142456)
7. Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing Extrahepatic Collateral Vessels That Supply Hepatocellular Carcinoma to Avoid Complications of Transcatheter Arterial Chemoembolization. Radiographics 2005;25 Suppl 1:S25-39. (Pubitemid 41686060)
8. Chung JW, Kim HC, Yoon JH, Lee HS, Jae HJ, Lee W, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: Prevalence and causative factors of extrahepatic collateral arteries in 479 patients. Korean J Radiol 2006;7:257-66. (Pubitemid 44905084)
9. Cheng LF, Ma KF, Fan WC, Yung AW, Li TM, Wong CS. Hepatocellular carcinoma with extrahepatic collateral arterial supply. J Med Imaging Radiat Oncol 2010;54:26-34.
10. Kim HC, Chung JW, Choi SH, Yoon JH, Lee HS, Jae HJ, et al. Hepatocellular carcinoma with internal mammary artery supply: Feasibility and efficacy of transarterial chemoembolization and factors affecting patient prognosis. J Vasc Interv Radiol 2007;18:611-9. (Pubitemid 46671576)
11. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, et al. Chemoembolization for the Treatment of Large Hepatocellular Carcinoma. J Vasc Interv Radiol 2010;21:1226-34.
12. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the study of liver. J Hepatol 2001;35:421-30.
13. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Sem Liv Dis 1999;19:329-38.
14. Nakai M, Sato M, Kawai N, Minamiguchi H, Masuda M, Tanihata H, et al. Hepatocellular Carcinoma: Involvement of the internal mammary artery. Radiology 2001;219:147-52. (Pubitemid 32234066)
15. Michels NA. Collateral arterial pathways to the liver after ligation of the hepatic artery and removal of the celiac axis. Cancer 1953;6:708-24.
16. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta analysis of randomized controlled trials. Radiology 2002;224:47-54. (Pubitemid 34680374)
17. Iwazawa J, Ohue S, Mitani T, Abe H, Hashimoto N, Hamuro M, et al. Identifying Feeding Arteries During TACE of Hepatic Tumors: Comparison of C- Arm CT and Digital Subtraction Angiography. AJR Am J Roentgenol 2009;192:1057-63.
18. Arora R, Soulen MC, Haskal ZJ. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 1999;10:1351-6.
19. Hirakawa M, Iida M, Aoyagi K, Matsui T, Akagi K, Fujishima M. Gastroduodenal lesions after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Gastroenterol 1988;83:837-40.
20. Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, et al. Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40.